nach oben

16.04.2024 | Review

Current Imaging Approaches in Inflammatory Breast Cancer

verfasst von: Miral M. Patel, Huong T. Le-Petross, Megha M. Kapoor, Janet A. Farag, Gary Whitman, Mary S. Guirguis

Erschienen in: Current Breast Cancer Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Inflammatory breast cancer (IBC) is a rare and aggressive type of breast cancer with a rapid clinical onset and a poor prognosis. The nonspecific clinical criteria have resulted in a difficult and delayed diagnosis of this rare disease. Radiologists’ awareness of the appropriate imaging modalities and features of IBC can improve prompt diagnosis, accurate staging of this aggressive disease, and early detection of distant metastases.

Recent Findings

Diffuse erythema and severe breast edema involving over one-third of the breast may obscure an identifiable mass on mammography and ultrasound (US) in patients with suspected IBC. Due to utilization of contrast, breast magnetic resonance imaging (MRI) allows exquisite details of breast lesions and is a superior diagnostic modality for IBC. Additionally, breast MRI and Fluorodeoxyglucose positron emission tomography computer tomography (FDG PET-CT) have become standard of care in the staging of IBC patients at the time of presentation.

Summary

Clinical presentation combined with mammography, US, and MRI have become standard of care in the diagnosis of IBC. The improved detection and diagnosis using a multimodality approach can contribute towards improved survival. Breast MRI is also beneficial to evaluate treatment response in patients after diagnosis. FDG PET-CT plays a significant role in establishing metastatic disease at the time of initial diagnosis.

Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, et al. Inflammatory breast cancer: what to know about this unique, aggressive breast cancer. Surg Clin North Am. 2018;98(4):787–800. https://doi.org/10.1016/j.suc.2018.03.009.CrossRefPubMed

Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23. https://doi.org/10.1093/annonc/mdq345.CrossRefPubMed

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–75. https://doi.org/10.1093/jnci/dji172.CrossRefPubMed

Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, et al. What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013;33(7):2003–17. https://doi.org/10.1148/rg.337135503.CrossRefPubMed

Yang WT, Le-Petross HT, Macapinlac H, Carkaci S, Gonzalez-Angulo AM, Dawood S, et al. Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat. 2008;109(3):417–26. https://doi.org/10.1007/s10549-007-9671-z.CrossRefPubMed

Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carcinoma: mammographic, ultrasonographic, clinical, and pathologic findings in 142 cases. Radiology. 2002;223(3):829–38. https://doi.org/10.1148/radiol.2233010198.CrossRefPubMed

Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17(7):891–9. https://doi.org/10.1634/theoncologist.2012-0039.CrossRefPubMedPubMedCentral

Schairer C, Hablas A, Eldein IAS, Gaafar R, Rais H, Mezlini A, et al. Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. Breast Cancer Res Treat. 2019;176(2):407–17. https://doi.org/10.1007/s10549-019-05237-5.CrossRefPubMedPubMedCentral

Devi GR, Fish LJ, Bennion A, Sawin GE, Weaver SM, Reddy K, et al. Identification of barriers at the primary care provider level to improve inflammatory breast cancer diagnosis and management. Prev Med Rep. 2023;36:102519. https://doi.org/10.1016/j.pmedr.2023.102519.CrossRefPubMedPubMedCentral

10.

•• Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(2):235–43. https://doi.org/10.1007/s10549-021-06434-x. (This article highlights an iniative to create more objective crtiera for IBC diagnosis.)CrossRefPubMedPubMedCentral

11.

Evans A, Sim YT, Lawson B, Macaskill J, Jordan L, Thompson A. The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease. Breast Cancer. 2022;29(2):296–301. https://doi.org/10.1007/s12282-021-01311-3.CrossRefPubMed

12.

Loonis AT, Chesebro AL, Bay CP, Portnow LH, Weiss A, Chikarmane SA, et al. Positive predictive value of axillary lymph node cortical thickness and nodal, clinical, and tumor characteristics in newly diagnosed breast cancer patients. Breast Cancer Res Treat. 2024;203(3):511–21. https://doi.org/10.1007/s10549-023-07155-z.CrossRefPubMed

13.

Mendelson EB, Böhm-Vélez M, Berg WA, et al. ACR BI-RADS® ultrasound. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. In:Reston, VA: American College of Radiology. 2013.

14.

Kamal RM, Hamed ST, Salem DS. Classification of inflammatory breast disorders and step by step diagnosis. Breast J. 2009;15(4):367–80. https://doi.org/10.1111/j.1524-4741.2009.00740.x.CrossRefPubMed

15.

Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, et al. MRI features of inflammatory breast cancer. AJR Am J Roentgenol. 2011;197(4):W769–76. https://doi.org/10.2214/AJR.10.6157.CrossRefPubMed

16.

Harada TL, Uematsu T, Nakashima K, Kawabata T, Nishimura S, Takahashi K, et al. Evaluation of breast edema findings at T2-weighted breast MRI is useful for diagnosing occult inflammatory breast cancer and can predict prognosis after neoadjuvant chemotherapy. Radiology. 2021;299(1):53–62. https://doi.org/10.1148/radiol.2021202604.CrossRefPubMed

17.

Hirko KA, Soliman AS, Banerjee M, Ruterbusch J, Harford JB, Merajver SD, et al. A comparison of criteria to identify inflammatory breast cancer cases from medical records and the surveillance, epidemiology and end results data base, 2007–2009. Breast J. 2014;20(2):185–91. https://doi.org/10.1111/tbj.12234.CrossRefPubMed

18.

Adeyefa M, Wei W, Yang W, Candelaria R, Hobbs B, Woodward W, Le-Petross, H. Differences in MIPS imaging of inflammatory breast cancer versus non-inflammatory breast cancer. ARRS 2016 Annual Meeting. Abstract 1047, SS22.

19.

Kul S, Cansu A, Alhan E, Dinc H, Reis A, Can G. Contrast-enhanced MR angiography of the breast: evaluation of ipsilateral increased vascularity and adjacent vessel sign in the characterization of breast lesions. AJR Am J Roentgenol. 2010;195(5):1250–4. https://doi.org/10.2214/AJR.10.4368.CrossRefPubMed

20.

Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, et al. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer. 2020;6(1):63. https://doi.org/10.1038/s41523-020-00203-7.CrossRefPubMedPubMedCentral

21.

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial. Radiology. 2018;289(3):618–27. https://doi.org/10.1148/radiol.2018180273.CrossRefPubMed

22.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, et al. Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016;279(1):44–55. https://doi.org/10.1148/radiol.2015150013.CrossRefPubMed

23.

Wright FC, Zubovits J, Gardner S, Fitzgerald B, Clemons M, Quan ML, et al. Optimal assessment of residual disease after neo-adjuvant therapy for locally advanced and inflammatory breast cancer–clinical examination, mammography, or magnetic resonance imaging? J Surg Oncol. 2010;101(7):604–10. https://doi.org/10.1002/jso.21559.CrossRefPubMed

24.

Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691–722. https://doi.org/10.6004/jnccn.2022.0030.CrossRefPubMed

25.

Groheux D, Giacchetti S, Delord M, Hindie E, Vercellino L, Cuvier C, et al. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med. 2013;54(1):5–11. https://doi.org/10.2967/jnumed.112.106864.CrossRefPubMed

26.

Patel MM, Le-Petross HT. Baseline FDG PET-CT imaging is necessary for newly diagnosed inflammatory breast cancer patients: a narrative review. Chin Clin Oncol. 2021;10(6):56. https://doi.org/10.21037/cco-21-82.CrossRefPubMed

27.

Chippa V, Barazi H. Inflammatory breast cancer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. [Updated 2023 Apr 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564324/.

28.

Carkaci S, Macapinlac HA, Cristofanilli M, Mawlawi O, Rohren E, Gonzalez Angulo AM, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50(2):231–8. https://doi.org/10.2967/jnumed.108.056010.CrossRefPubMed

29.

Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115(21):5038–47. https://doi.org/10.1002/cncr.24534.CrossRefPubMed

30.

Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi MA, Mawlawi O, et al. Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant? Acad Radiol. 2012;19(5):535–41. https://doi.org/10.1016/j.acra.2012.01.001.CrossRefPubMedPubMedCentral

31.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, et al. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017;18(4):e228–32. https://doi.org/10.1016/S1470-2045(17)30192-4.CrossRefPubMedPubMedCentral

32.

•• Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, et al. Validation of prognostic stage and anatomic stage in the American Joint committee on cancer 8th edition for inflammatory breast cancer. Cancers (Basel). 2020;12(11). https://doi.org/10.3390/cancers12113105. (This study found that the addition of biological factors in the traditional staging system in the AJCC's 8^th edition allows more accurate prognostication in IBC patients.)

33.

National Comprehensive Cancer Network: Breast Cancer (Version 1.2024). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (2024). Accessed March 5, 2024.

34.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.CrossRefPubMed

35.

•• Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, et al. Factors associated with pathological node negativity in inflammatory breast cancer: are there patients who may be candidates for a de-escalation of axillary surgery? Ann Surg Oncol. 2020;27(12):4603–12. https://doi.org/10.1245/s10434-020-08891-y. (This study evaluated the rate of node negativity at final surgery post neoadjuvant chemotherapy for patients with IBC in an attempt to identify factors that can allow for potential less invasive axillary surgery in appropriate IBC patients.)CrossRefPubMed

Titel: Current Imaging Approaches in Inflammatory Breast Cancer
verfasst von: Miral M. Patel
Huong T. Le-Petross
Megha M. Kapoor
Janet A. Farag
Gary Whitman
Mary S. Guirguis
Publikationsdatum: 16.04.2024
Verlag: Springer US
Erschienen in: Current Breast Cancer Reports
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-024-00546-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Current Imaging Approaches in Inflammatory Breast Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie